[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331935-105":59,"doc-detail-331935-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evolving-standards-and-future-directions-for-systemic-therapies-in-cervical-cancer","Evolving standards and future directions for systemic therapies in cervical cancer","","Groundbreaking 2023 clinical trials are summarized for locally advanced and persistent, recurrent, or metastatic cervical cancers, including INTERLACE and KEYNOTE-A18 in the locally advanced setting and BEATcc, innovaTV 301, and DESTINY-PanTumor02 in advanced disease. Practice implications of favorable results are interpreted using global health considerations, with updated treatment algorithms proposed. Emerging drug-development trends are discussed, emphasizing unmet needs after immune checkpoint inhibitor exposure and guiding next-generation trial populations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evolving-standards-and-future-directions-for-systemic-therapies-in-cervical-cancer/331935/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evolving-standards-and-future-directions-for-systemic-therapies-in-cervical-cancer/331935.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which 2023 trials are discussed for locally advanced cervical cancer?","Question",{"text":112,"@type":113},"The review focuses on INTERLACE and KEYNOTE-A18 for the locally advanced setting, interpreting their positive results for updated practice.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which trials are covered for advanced cervical disease?",{"text":117,"@type":113},"For advanced disease, the review describes BEATcc, innovaTV 301, and DESTINY-PanTumor02 and discusses how their findings inform treatment directions.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are next-generation trials considered necessary?",{"text":121,"@type":113},"As immune checkpoint inhibitors become more widely used, patients whose cancers persist, relapse, or progress after prior ICI exposure represent an unmet clinical need and a key target population for future trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},331935,1790679526,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","J Gynecol Oncol. 2024 Mar;35(2):e65 [https://doi.org/10.3802/jgo.2024.35.e65](https://doi.org/10.3802/jgo.2024.35.e65)[ ](https://doi.org/10.3802/jgo.2024.35.e65)pISSN 2005-0380·eISSN 2005-0399  \nReview Article  \nReceived: Dec 23, 2023  \nAccepted: Jan 5, 2024  \nPublished online: Jan 15, 2024  \nCorrespondence to  \nJack Junjie Chan  \nDivision of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583.  \nEmail: [jack.chan@duke-nus.edu.sg](jack.chan@duke-nus.edu.sg)  \n© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nDaniel Jia MingAng  [https://orcid.org/0000-0002-4053-2226](https://orcid.org/0000-0002-4053-2226)[ ](https://orcid.org/0000-0002-4053-2226)Jack Junjie Chan  [https://orcid.org/0000-0002-7214-8368](https://orcid.org/0000-0002-7214-8368)  \nConflict of Interest  \nA. D.J. M. has no conflict of interest to declare.  \nC.J.J. received honoraria from Merck Sharp & Dohme, GlaxoSmithKline and AstraZeneca; research funding from Bristol-Myers Squibb (institution); travel, accommodations, expenses from AstraZeneca, Merck KGaA and Roche; and held a consulting or advisory role in GlaxoSmithKline, Merck Sharp & Dohme and  \nEvolving standards and future directions for systemic therapies in cervical cancer  \nDaniel Jia Ming Ang ,1 Jack Junjie Chan  1,2  \n1Division of Medical Oncology, National Cancer Centre Singapore, Singapore 2Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore  \nABSTRACT  \nSeveral groundbreaking clinical trials with the potential to transform the management paradigm of both locally advanced and persistent, recurrent, or metastatic cervical cancers have been presented in 2023. This review describes the reported data from INTERLACE and KEYNOTE-A18 in the locally advanced setting, as well as BEATcc, innovaTV 301 and DESTINY-PanTumor02 for advanced disease. The practice implications of their positive results are interpreted in the context of global health considerations, and updated treatment algorithms are proposed. Furthermore, emerging trends in drug development for cervical cancer are discussed. As the routine use of immune checkpoint inhibitors (ICIs) for curative and palliative indications increases in the foreseeable future, patients whose cervical cancers which persist, relapse or progress after prior ICI exposure will represent an area ofunmet clinical need and form the key target population for next-generation trials. Future research will help shape oncologists’ approaches in the optimal selection, sequencing andre-treatment or rechallenge of immuno-oncology agents and/or antibody-drug conjugates in women with cervical cancer.  \nKeywords: Cervical Cancer; Chemoradiotherapy; Immune Checkpoint Inhibitors; Immunoconjugates; Adoptive Immunotherapy  \nSynopsis  \nThis review highlights the practice-changing trials of cervical cancer systemic therapies in 2023. New standards of care in locally advanced and persistent, recurrent, or metastatic disease are presented. Lastly, we outline future research directions which can inform selection and sequencing of emerging therapeutics.  \nINTRODUCTION  \nCervical cancer is the fourth most common cancer among females worldwide, contributing to substantial morbidity and mortality [1,2] . While breakthroughs in cervical cancer management have occurred over past decades, 2023 was annus mirabilis because of multiple reported impactful studies which alter the systemic treatment paradigms for locally advanced  \n[https://ejgo.org](https://ejgo.org) 1/14  \nNew standards","cbCairhNa9no1HYJ","https://ap.wps.com/l/cbCairhNa9no1HYJ","pdf",3174897,14,"English","# Abstract\n# Introduction\n## LACC\n## INTERLACE","[{\"question\":\"Which 2023 trials are discussed for locally advanced cervical cancer?\",\"answer\":\"The review focuses on INTERLACE and KEYNOTE-A18 for the locally advanced setting, interpreting their positive results for updated practice.\"},{\"question\":\"Which trials are covered for advanced cervical disease?\",\"answer\":\"For advanced disease, the review describes BEATcc, innovaTV 301, and DESTINY-PanTumor02 and discusses how their findings inform treatment directions.\"},{\"question\":\"Why are next-generation trials considered necessary?\",\"answer\":\"As immune checkpoint inhibitors become more widely used, patients whose cancers persist, relapse, or progress after prior ICI exposure represent an unmet clinical need and a key target population for future trials.\"}]","Evolving standards and future directions for systemic therapies in cervical cancer | PDF",1789995840,35]